LouiseMThurmanMD

Psychiatry • Oklahoma City, OK

Physician

Join to view full profile

Dr. Thurman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thurman's full profile

Already have an account?

Office
1111 N Lee Ave
Suite 400
Oklahoma City, OK 73103
Phone+1 405-235-8188

Fax+1 405-235-9919

Education & Training

San Mateo County Behavioral Health and Recovery ServicesResidency, Psychiatry, 1986 - 1993
University of California, Davis, School of MedicineClass of 1987

Certifications & Licensure

CA State Medical License 1990 - 2026
OK State Medical License 1993 - 2024
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
PRC-063 in Adolescent ADHD Start of enrollment: 2014 Apr 01
Completed
Phase 3
Open-label Safety Study in Adults With ADHD Start of enrollment: 2014 Jun 01
Completed
Phase 3
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD Start of enrollment: 2014 May 01
Completed
Phase 3
Dasotraline SEP360-105 Pediatric PK/PD Study Start of enrollment: 2014 Jul 01
Completed
Phase 1
Dasotraline Pediatric ADHD Study Start of enrollment: 2015 Apr 01
Completed
Phase 2, Phase 3
Dasotraline Pediatric Extension Study Start of enrollment: 2015 Jun 30
Completed
Phase 3
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting Start of enrollment: 2015 Aug 01
Completed
Phase 3
Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD Start of enrollment: 2016 Jan 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

6 citations
Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.
Sarah Atkinson, Louise Thurman, Sara Ramaker, Gina Buckley, Sarah Ruta Jones
CNS Spectrums. 2019-10-01